Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Poll






Jul 18, 2011

Clinical Trial Strategy

Unlike large biopharma firms, most small biotech companies usually have their fortunes riding on only a single drug. If a small firm’s product fails a Phase II trial, do you think the smart move is to keep working on its product candidate instead of entirely scrapping the project?

If a firm’s only candidate fails a Phase II trial, should it push on with development?

Yes
 
  33.8%
No
 
  43.2%
Undecided
 
  23.0%



Related content